Logo

Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

Share this
Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

Xbrane Biopharma Reports Results of Xlucane Compared to Lucentis from In-Vivo Study

Shots:
  • The in-vivo study was evaluated on group of rabbits administering bilateral intravitreal injection of Xlucane (ranibisumab- Lucentis biosimilar) vs Lucentis divided in two equal groups- testing its PK and tolerability in both the serum and the eyeglass body
  • The results show Xlucane is well tolerated with no ocular inflammation in eyes- with equivalent PK observed in the serum and eyeglass body
  • Xlucane is a mAb- being developed as biosimilar of Lucentis. Lucentis is approved for the treatment of Diabetic Retinopathy & Macular Edema- mCNV- Wet AMD and Macular Edema Following RVO
| Ref: Xbrane Biopharma | Image: Xbrane Biopharma

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions